Ablative Therapies for Breast Cancer:  State of Art

Carriero, Serena; Lanza, Carolina; Pellegrino, Giuseppe; Ascenti, Velio; Sattin, Caterina; Pizzi, Caterina; Angileri, Salvatore Alessio; Biondetti, Pierpaolo; Ianniello, Andrea; Piacentino, Filippo; Lavorato, Roberto; Ierardi, Anna Maria; Carrafiello, Gianpaolo

doi:10.1177/15330338231157193

Cited by 20 publications

(11 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefits of microwave ablation include higher constant intratumoral temperatures and faster ablation times than those of RFA in breast tumors [ 7 ]. In our study, the mean ablation time was 4.2 min.…”

Section: Discussionmentioning

confidence: 99%

“…Percutaneous ablation techniques, such as cryoablation, radiofrequency ablation (RFA), laser ablation, microwave irradiation, high-intensity focused ultrasound (HIFU), and electroporation offered their own advantages and disadvantages in terms of success rates and degrees of ablation [ 4 – 6 ]. Microwave ablation produces relatively high intratumoral temperatures, resulting in larger ablation zones within a short duration and the use of one single probe [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MR-guided percutaneous microwave coagulation of small breast tumors

Ji,

Zhuo,

et al. 2024

Insights Imaging

View full text Add to dashboard Cite

Background To evaluate the technical success and patient safety of magnetic resonance-guided percutaneous microwave coagulation (MR-guided PMC) for breast malignancies. Methods From May 2018 to December 2019, 26 patients with breast tumors measuring 2 cm or less were recruited to participate in a prospective, single-institution clinical study. The primary endpoint of this study was the evaluation of treatment efficacy for each patient. Histochemical staining with α-nicotinamide adenine dinucleotide and reduced (NADH)-diaphorase was used to determine cell viability following and efficacy of PMC. The complications and self-reported sensations from all patients during and after ablation were also assessed. The technical success of the PMC procedure was defined when the area of the NADH-diaphorase negative region fully covered the hematoxylin–eosin (H&E) staining region in the tumor. Results All patients had a complete response to ablation with no residual carcinoma on histopathological specimen. The mean energy, ablation duration, and procedure duration per tumor were 36.0 ± 4.2 kJ, 252.9 ± 30.9 S, and 104.2 ± 13.5 min, respectively. During the ablation, 14 patients underwent prolonged ablation time, and 1 patient required adjusting of the antenna position. Eleven patients had feelings of subtle heat or swelling, and 3 patients experienced slight pain. After ablation, one patient took two painkillers because of moderate pain, and no patients had postoperative oozing or other complications after PMC. Induration around the ablation area appeared in 16 patients. Conclusion MR-guided PMC of small breast tumors is feasible and could be applied in clinical practice in the future. Critical relevance statement MR-guided PMC of small breast tumors is feasible and could be applied in clinical practice in the future. Key points • MR-guided PMC of small breast tumors is feasible. • PMC was successfully performed for all patients. • All patients were satisfied with the final cosmetic result. Graphical Abstract

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MR-guided percutaneous microwave coagulation of small breast tumors

Ji,

Zhuo,

et al. 2024

Insights Imaging

View full text Add to dashboard Cite

show abstract

“…21 Not only is it still in use, but many reviews and original scientific papers are still being published on its usability, safety, different formulation improvements, and targeted therapies. Initially, DOX was confirmed to be effective for a few types of tumors only, although it is now used in many treatments to stop the growth of cancer cells in bones, 93,94 liver, 97,102 prostate, 99,101 cervical tissue, 100 breasts, 87,89,95,96,98,108 pancreas, 86,103 lung, 99,104 ovarium, 105 colon, 106,107 and the brain. 92 Considering all the scientific evidence presented in this section, future research should focus on formulation improvement and the safety profile of the FRLs used as antioxidants to protect organs from toxicity in DOX-related treatments.…”

Section: Frl As Potential Organ Protector In Oncology Treatmentsmentioning

confidence: 99%

Potential Medical Use of Fullerenols After Two Decades of Oncology Research

Injac

2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Fullerenes are carbon molecules that are found in nature in various forms. They are composed of hexagonal and pentagonal rings that create closed structures. Almost 4 decades ago, fullerenes were identified in the form of C60 and C70, and following the award of the Nobel Prize in Chemistry for this discovery in 1996, many laboratories started working on their water-soluble derivatives that could be used in different industries, including pharmaceutical industries. One of the first fullerene forms that was the focus of different research groups was fullerenol, C60(OH) n ( n = 2-44). Both in-vitro and in-vivo studies have shown that polyhydroxylate fullerene derivatives can potentially be used as either antioxidative agents or cytostatics (depending on their co-administration, forms, and concentration/dose) in biological systems. The current review aimed to present a critical view of the potential applications and limitations of fullerenols in oncology, as understood from the past 2 decades of research.

show abstract

“…The most studied and widely used nonsurgical ablative techniques for the treatment of breast cancer include cryoablation, high-intensity focused ultrasound surgery (HIFU), radiofrequency ablation (RFA), microwave ablation (MWA), and laser ablation (LA) [5,6].…”

Section: Introductionmentioning

confidence: 99%

Percutaneous Ultrasound-Guided Cryoablation for Early-Stage Primary Breast Cancer- A follow-up study in Japan

Kawamoto,

Tsugawa,

Furuya

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Ultrasound guided percutaneous cryoablation (PCA) for early-stage breast cancer (ESBC) can be performed under local anesthesia in an outpatient clinic. This study continues a pilot stage to examine local control, safety, patient quality of life (QoL), satisfaction and cosmetic outcomes of cryoablation for ESBC. Methods PCA was performed under local anesthesia for patients with primary ESBC, followed by radiation and endocrine therapies. Oncologic outcomes were examined by imaging (mammography, ultrasound, MRI) at baseline and 1, 6, 12, 24, 36, and 60 months post-cryoablation. EQ-VAS, EQ-5D-5L, subjective satisfaction and Moiré topography were used to measure health-related QoL outcomes. Results Eighteen patients, mean aged 59.0±9.0 years, mean tumor size 9.8±2.3mm, ER+, PR+ (17/18), HER2-, Ki67<20% (15/18), underwent PCA and were followed for a mean of 44.3 months. No serious adverse events were reported, and no patients had local recurrence or distant metastasis in the 5-year follow-up. Cosmetic outcomes, satisfaction level, and QoL all improved post-cryoablation. Five-year average reduction rates of the cryolesion long, short, and depth diameters, on US, were 61.3%, 42.3%, and 22.8%, respectively, compared to the 86.2% volume reduction rate on MRI. The correlation coefficient between MRI and US measurement criteria was highest for the long diameter. During follow-up, calcification of the treated area was observed in 13/18 cases. Conclusion Cryoablation for ESBC is an effective and safe procedure with excellent cosmetic outcomes and improved QoL. This study contributes to the growing evidence supporting cryoablation as a potential standard treatment for ESBC, given compliance to pre-defined patient selection criteria.

show abstract

Ablative Therapies for Breast Cancer: State of Art

Cited by 20 publications

References 72 publications

MR-guided percutaneous microwave coagulation of small breast tumors

MR-guided percutaneous microwave coagulation of small breast tumors

Potential Medical Use of Fullerenols After Two Decades of Oncology Research

Percutaneous Ultrasound-Guided Cryoablation for Early-Stage Primary Breast Cancer- A follow-up study in Japan

Contact Info

Product

Resources

About